IndraLab

Statements

Baricitinib inhibits STAT1. 5 / 5
| 5
reach
"Although baricitinib completely inhibited the IFN stimulated activation of STAT1, the effects on DCs were partial; baricitinib has almost no inhibitory effect on Tyk2, allowing persistent activity of the Tyk2 pathway for IRF7."
30002661
reach
"In this case, therapy with baricitinib effectively blocked IFN-alpha activation and reduced STAT1 signaling but had no effect on the progression of the neurological disease."
36685504
reach
"The data in Figure 5 suggests that baricitinib, which negatively regulates STAT1 and pSTAT1, overrides the elevated innate immunity associated with SAMHD1 loss."
35085552
reach
"Addition of ruxolitinib and baricitinib inhibited STAT1 hyperactivation in STAT1-GoF EPSC in a dose-dependent manner, which was not observed with tofacitinib."
38072195
reach
"Meanwhile, baricitinib downregulated the expression levels of Transcription factors (Stat1, Stat4, Stat3, Stat5a, Bcl6) (Figure 5C)."
38487164